Wave Life Sciences shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and announced a $12 price target.
Portfolio Pulse from Benzinga Newsdesk
Wave Life Sciences' stock (WVE) is trading higher following an upgrade from Leerink Partners, changing its rating from Market Perform to Outperform with a new price target of $12.
December 19, 2023 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wave Life Sciences' stock is expected to experience positive momentum after Leerink Partners upgraded the stock to Outperform and set a price target of $12, indicating a bullish outlook.
Analyst upgrades typically lead to positive short-term price movement as they reflect a positive change in the stock's outlook. The new price target of $12 suggests significant upside potential from current levels, which can attract investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100